Byrne RA, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S, et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J. 2015;36:2608–20.
Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, et al. Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 Consensus Document. Circulation. 2018;137:2635–50.
Farb A, Zuckerman BD. Clinical event adjudication in cardiovascular device trials: an Food and Drug Administration perspective. Am Heart J. 2017;191:62–4.
West JW, Guzman SV. Coronary dilatation and constriction visualized by selective arteriography. Circ Res. 1959;7:527–36.
Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51:5–40.
Zir LM, Miller SW, Dinsmore RE, Gilbert JP, Harthorne JW. Interobserver variability in coronary angiography. Circulation. 1976;53:627–32.
Gensini GG, Kelly AE, Da Costa BC, Huntington PP. Quantitative angiography: the measurement of coronary vasomobility in the intact animal and man. Chest. 1971;60:522–30.
Brown BG, Bolson E, Frimer M, Dodge HT. Quantitative coronary arteriography: estimation of dimensions, hemodynamic resistance, and atheroma mass of coronary artery lesions using the arteriogram and digital computation. Circulation. 1977;55:329–37.
Serruys PW, Reiber JH, Wijns W, van den Brand M, Kooijman CJ, ten Katen HJ, et al. Assessment of percutaneous transluminal coronary angioplasty by quantitative coronary angiography: diameter versus densitometric area measurements. Am J Cardiol. 1984;54:482–8.
Kondo H, Ito S, Shigeyama J, Ito O, Matsushita T, Okamoto M, et al. Beneficial application of quantitative coronary angiography (edge detection algorithm) in analysis of dissected coronary arteries to predict long-term patency. Jpn Circ J. 2000;64:667–71.
Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331:489–95.
Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: 1-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007–11.
Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med. 1996;334:561–6.
Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Izumi M, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999;100:21–6.
Tsuchikane E, Sumitsuji S, Awata N, Nakamura T, Kobayashi T, Izumi M, et al. Final results of the STent versus directional coronary Atherectomy Randomized Trial (START). J Am Coll Cardiol. 1999;34:1050–7.
Suzuki T, Hosokawa H, Katoh O, Fujita T, Ueno K, Takase S, et al. Effects of adjunctive balloon angioplasty after intravascular ultrasound-guided optimal directional coronary atherectomy: the result of Adjunctive Balloon Angioplasty After Coronary Atherectomy Study (ABACAS). J Am Coll Cardiol. 1999;34:1028–35.
Kozuma K, Hara K, Yamasaki M, Morino Y, Ayabe S, Kuroda Y, et al. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz–Schatz coronary stent implantation. Am Heart J. 2001;141:124–30.
Nasu K, Tsuchikane E, Awata N, Matsumoto H, Shiota A, Takeda Y, et al. Quantitative angiographic and intravascular ultrasound study > 5 years after directional coronary atherectomy. Am J Cardiol. 2004;93:543–8.
Ikari Y, Sakurada M, Kozuma K, Kawano S, Katsuki T, Kimura K, et al. Upfront thrombus aspiration in primary coronary intervention for patients with ST-segment elevation acute myocardial infarction: report of the VAMPIRE (VAcuuM asPIration thrombus REmoval) trial. JACC Cardiovasc Interv. 2008;1:424–31.
Tsuchikane E, Suzuki T, Asakura Y, Oda H, Ueda K, Tanaka T, et al. Debulking of chronic coronary total occlusions with rotational or directional atherectomy before stenting: final results of DOCTORS study. Int J Cardiol. 2008;125:397–403.
Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the randomized evaluation of sirolimus-eluting versus everolimus-eluting stent trial (RESET). Circulation. 2012;126:1225–36.
Habara S, Iwabuchi M, Inoue N, Nakamura S, Asano R, Nanto S, et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J. 2013;166:527–33.
Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2013;62:181–90.
Natsuaki M, Kozuma K, Morimoto T, Shiomi H, Kimura T. Two-year outcome of a randomized trial comparing second-generation drug-eluting stents using biodegradable or durable polymer. JAMA. 2014;311:2125–7.
Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, et al. A randomized trial evaluating everolimus-eluting absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36:3332–42.
Ikari Y, Kyono H, Isshiki T, Ishizuka S, Nasu K, Sano K, et al. Usefulness of everolimus-eluting coronary stent implantation in patients on maintenance hemodialysis. Am J Cardiol. 2015;116:872–6.
Morino Y, Tobaru T, Yasuda S, Kataoka K, Tanabe K, Hirohata A, et al. Biodegradable polymer-based, argatroban-eluting, cobalt–chromium stent (JF-04) for treatment of native coronary lesions: final results of the first-in-man study and lessons learned. Eurointervention. 2016;12:1271–8.
Suzuki K, Ishikawa T, Mutoh M, Sakamoto H, Kubota T, Ogawa T, et al. Midterm angiographic outcomes with sirolimus- and everolimus-eluting stents for small vessels in diabetic patients: propensity-score-matched comparisons in three different vessel diameters. Cardiovasc Interv Ther. 2018;33:205–16.
Saito S, Krucoff MW, Nakamura S, Mehran R, Maehara A, Al-Khalidi HR, et al. Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich’s Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. Eur Heart J. 2018;39:2460–8.
Saito S, Ando K, Ito Y, Tobaru T, Yajima J, Kimura T, et al. Two-year results after coronary stenting of small vessels in Japanese population using 2.25-mm diameter sirolimus-eluting stent with bioresorbable polymer: primary and long-term outcomes of CENTURY JSV study. Cardiovasc Interv Ther. 2019;34:25–33.
Aoki J, Nakazawa G, Ando K, Nakamura S, Tobaru T, Sakurada M, et al. Effect of combination of non-slip element balloon and drug-coating balloon for in-stent restenosis lesions (ELEGANT study). J Cardiol. 2019;74:436–42.
Onishi T, Onishi Y, Kobayashi I, Umezawa S, Niwa A. Drug-coated balloon angioplasty for de novo small vessel disease including chronic total occlusion and bifurcation in real-world clinical practice. Cardiovasc Interv Ther. 2019;34:139–48.
Nagai T, Mizobuchi M, Funatsu A, Kobayashi T, Nakamura S. Acute and mid-term outcomes of drug-coated balloon following rotational atherectomy. Cardiovasc Interv Ther. 2019. https://doi.org/10.1007/s12928-019-00611-y.
Matsuo H, Kawase Y. FFR and iFR guided percutaneous coronary intervention. Cardiovasc Interv Ther. 2016;31:183–95.
Kawase Y, Matsuo H, Akasaka T, Shiono Y, Tanaka N, Amano T, et al. Clinical use of physiological lesion assessment using pressure guidewires: an expert consensus document of the Japanese Association of Cardiovascular Intervention and Therapeutics. Cardiovasc Interv Ther. 2019;34:85–96.
Saito T, Misaki M, Shirato K, Takishima T. Three-dimensional quantitative coronary angiography. IEEE Trans Biomed Eng. 1990;37:768–77.
Nishi T, Kitahara H, Fujimoto Y, Nakayama T, Sugimoto K, Takahara M, et al. Comparison of 3-dimensional and 2-dimensional quantitative coronary angiography and intravascular ultrasound for functional assessment of coronary lesions. J Cardiol. 2017;69:280–6.
Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, et al. Diagnostic accuracy of fast computational approaches to derive fractional flow reserve from diagnostic coronary angiography: the International Multicenter FAVOR Pilot Study. JACC Cardiovasc Interv. 2016;9:2024–35.
Wunderlich W, Fischer F, Linderer T, Kirkeeide RL. Analytic isocenter calibration. A new approach for accurate X-ray gantries. Angiology. 1995;46:577–82.
Hess OM, Buchi M, Kirkeeide RL, Muser M, Osenberg H, Niederer P, et al. Quantitative coronary arteriography at rest and during exercise. In: Reiber JHC, Serruys PW, editors. Quantitative coronary arteriography. Dordrecht: Springer; 1991. p. 145–53.
Tomkowiak MT, Speidel MA, Raval AN, Van Lysel MS. Calibration-free device sizing using an inverse geometry X-ray system. Med Phys. 2011;38:283–93.
Ito S, Kinoshita K, Endo A, Nakamura M, Muramatsu T. Impact of catheter size on reliability of quantitative coronary angiographic measurements (comparison of 4Fr and 6Fr catheters). Heart Vessels. 2016;31:1752–7.
Tadehara F, Imazu M, Kono S, Sano K. Calibration with currently available low-radiopacity catheters for scaling in digital quantitative coronary angiography. Investig Radiol. 2001;36:705–12.
Sabate M, Costa MA, Kozuma K, Kay IP, van der Giessen WJ, Coen VL, et al. Geographic miss: a cause of treatment failure in radio-oncology applied to intracoronary radiation therapy. Circulation. 2000;101:2467–71.
Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–23.
Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol. 2008;51:23–32.
Ito S, Kinoshita K, Endo A, Nakamura M. Impact of cine frame selection on quantitative coronary angiography results. Clin Med Insights Cardiol. 2019;13:1179546819838232.
Kozuma K, Kashiwabara K, Shinozaki T, Oba K, Matsuyama Y. Two-by-two cross-over study to evaluate agreement between versions of a quantitative coronary analysis system (QAngio XA). Int J Cardiovasc Imaging. 2017;33:779–87.
Kubo T, Akasaka T, Shite J, Suzuki T, Uemura S, Yu B, et al. OCT compared with IVUS in a coronary lesion assessment: the OPUS-CLASS study. JACC Cardiovasc Imaging. 2013;6:1095–104.
Sotomi Y, Onuma Y, Miyazaki Y, Asano T, Katagiri Y, Tenekecioglu E, et al. Is quantitative coronary angiography reliable in assessing the late lumen loss of the everolimus-eluting bioresorbable polylactide scaffold in comparison with the cobalt–chromium metallic stent? Eurointervention. 2017;13:e585–94.
Costa MA, Sabate M, Angiolillo DJ, Hu P, Jimenez-Quevedo P, Corros C, et al. Relocation of minimal luminal diameter after bare metal and drug-eluting stent implantation: incidence and impact on angiographic late loss. Catheter Cardiovasc Interv. 2007;69:181–8.
Huo Y, Finet G, Lefevre T, Louvard Y, Moussa I, Kassab GS. Optimal diameter of diseased bifurcation segment: a practical rule for percutaneous coronary intervention. Eurointervention. 2012;7:1310–6.
Lansky A, Tuinenburg J, Costa M, Maeng M, Koning G, Popma J, et al. Quantitative angiographic methods for bifurcation lesions: a consensus statement from the European Bifurcation Group. Catheter Cardiovasc Interv. 2009;73:258–66.
Ishibashi Y, Grundeken MJ, Nakatani S, Iqbal J, Morel MA, Genereux P, et al. In vitro validation and comparison of different software packages or algorithms for coronary bifurcation analysis using calibrated phantoms: implications for clinical practice and research of bifurcation stenting. Catheter Cardiovasc Interv. 2015;85:554–63.
Girasis C, Onuma Y, Schuurbiers JC, Morel MA, van Es GA, van Geuns RJ, et al. Validity and variability in visual assessment of stenosis severity in phantom bifurcation lesions: a survey in experts during the fifth meeting of the European Bifurcation Club. Catheter Cardiovasc Interv. 2012;79:361–8.
Di Mario C, Sutaria N. Coronary angiography in the angioplasty era: projections with a meaning. Heart. 2005;91:968–76.
Klein JL, Hoff JG, Peifer JW, Folks R, Cooke CD, King SB 3rd, et al. A quantitative evaluation of the three dimensional reconstruction of patients’ coronary arteries. Int J Card Imaging. 1998;14:75–87.
Dvir D, Marom H, Guetta V, Kornowski R. Three-dimensional coronary reconstruction from routine single-plane coronary angiograms: in vivo quantitative validation. Int J Cardiovasc Intervent. 2005;7:141–5.
Yong AS, Ng AC, Brieger D, Lowe HC, Ng MK, Kritharides L. Three-dimensional and two-dimensional quantitative coronary angiography, and their prediction of reduced fractional flow reserve. Eur Heart J. 2011;32:345–53.
Onuma Y, Girasis C, Aben JP, Sarno G, Piazza N, Lokkerbol C, et al. A novel dedicated 3-dimensional quantitative coronary analysis methodology for bifurcation lesions. Eurointervention. 2011;7:629–35.
Girasis C, Schuurbiers JC, Muramatsu T, Aben JP, Onuma Y, Soekhradj S, et al. Advanced three-dimensional quantitative coronary angiographic assessment of bifurcation lesions: methodology and phantom validation. Eurointervention. 2013;8:1451–60.
Group TS. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312:932–6.
Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879–88.
Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125–30.
Ross AM, Neuhaus KL, Ellis SG. Frequent lack of correspondence among core laboratories in assessing TIMI flow grade after reperfusion therapy. Circulation. 1995;92:I–345.
Tanedo JS, Kelly RF, Marquez M, Burns DE, Klein LW, Costanzo MR, et al. Assessing coronary blood flow dynamics with the TIMI frame count method: comparison with simultaneous intracoronary Doppler and ultrasound. Catheter Cardiovasc Interv. 2001;53:459–63.
Pijls NH, van Son JA, Kirkeeide RL, De Bruyne B, Gould KL. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation. 1993;87:1354–67.
De Bruyne B, Baudhuin T, Melin JA, Pijls NH, Sys SU, Bol A, et al. Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography. Circulation. 1994;89:1013–22.
Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, vant’t Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213–24.
De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991–1001.
Morris PD, Ryan D, Morton AC, Lycett R, Lawford PV, Hose DR, et al. Virtual fractional flow reserve from coronary angiography: modeling the significance of coronary lesions: results from the VIRTU-1 (VIRTUal Fractional Flow Reserve From Coronary Angiography) study. JACC Cardiovasc Interv. 2013;6:149–57.
Papafaklis MI, Muramatsu T, Ishibashi Y, Lakkas LS, Nakatani S, Bourantas CV, et al. Fast virtual functional assessment of intermediate coronary lesions using routine angiographic data and blood flow simulation in humans: comparison with pressure wire—fractional flow reserve. Eurointervention. 2014;10:574–83.
Collet C, Onuma Y, Sonck J, Asano T, Vandeloo B, Kornowski R, et al. Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis. Eur Heart J. 2018;39:3314–21.
Sejr-Hansen M, Westra J, Thim T, Christiansen EH, Eftekhari A, Kristensen SD, et al. Quantitative flow ratio for immediate assessment of nonculprit lesions in patients with ST-segment elevation myocardial infarction-An iSTEMI substudy. Catheter Cardiovasc Interv. 2019;94:686–92.
Kogame N, Takahashi K, Tomaniak M, Chichareon P, Modolo R, Chang CC, et al. Clinical implication of quantitative flow ratio after percutaneous coronary intervention for 3-vessel disease. JACC Cardiovasc Interv. 2019;12:2064–75.
Asano T, Katagiri Y, Chang CC, Kogame N, Chichareon P, Takahashi K, et al. Angiography-derived fractional flow reserve in the SYNTAX II trial: feasibility, diagnostic performance of quantitative flow ratio, and clinical prognostic value of functional SYNTAX score derived from quantitative flow ratio in patients with 3-vessel disease. JACC Cardiovasc Interv. 2019;12:259–70.
Suzuki N, Nishide S, Kimura T, Aoyagi T, Kanamori K, Shiratori Y, et al. Relationship of quantitative flow ratio after second-generation drug-eluting stent implantation to clinical outcomes. Heart Vessels. 2019. https://doi.org/10.1007/s00380-019-01545-4.
Hamaya R, Hoshino M, Kanno Y, Yamaguchi M, Ohya H, Sumino Y, et al. Prognostic implication of three-vessel contrast-flow quantitative flow ratio in patients with stable coronary artery disease. Eurointervention. 2019;15:180–8.
Asano T, Katagiri Y, Collet C, Tenekecioglu E, Miyazaki Y, Sotomi Y, et al. Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy. Eurointervention. 2018;14:e570–9.
Asano T, Serruys PW, Collet C, Miyazaki Y, Takahashi K, Chichareon P, et al. Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. Eur Heart J. 2018;39:3381–9.
Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol. 1974;33:87–94.